IPO FILING: BioForm Medical (BFRM)

Print Email

A company named BioForm Medical has filed to come public vian an initial public offering.  For registration purposes, it has a proposed sale of up to $115 million in common stock under the proposed "BFRM" ticker on NASDAQ.  The lead underwriters are listed as JPMorgan and Piper Jaffray, and co-managers are listed as CIBC and Jefferies.

BioForm is a medical aesthetics company focused on products that are used by physicians to enhance a patient’s appearance. Its core product is Radiesse, an injectable dermal filler designed to provide long-lasting, cost-effective and safe aesthetic improvement for patients. The clinical studies in various stages have demonstrated that Radiesse provides meaningful initial aesthetic correction and approximately 12 months’ duration of aesthetic improvement in many patients. It also said that physicians have used Radiesse for more than five years and it has shipped over 500,000 syringes worldwide. BioForm has also obtained licenses to two products: Aethoxysklerol, a drug product which is currently in a Phase III trial for the treatment of spider and reticular veins; and BioGlue, a surgical adhesive in clinical testing for tissue fixation in browplasty, or forehead lift.

For the fiscal year ended June 30, 2007 revenues were $47.4 million representing a 109% increase over the prior fiscal year. BioForm currently markets products through a direct sales force of over 100 sales representatives in the United States and Europe and a network of third party distributors in more than 30 countries.  Primary customers are dermatologists, plastic surgeons and facial plastic surgeons.  This are high-end as their aesthetics products are not reimbursed by insurers and are paid for entirely and directly by patients.

Jon C. Ogg
August 21, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.